Halozyme Therapeutics, Inc. $HALO Holdings Trimmed by Hodges Capital Management Inc.

Hodges Capital Management Inc. lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.0% in the third quarter, Holdings Channel.com reports. The firm owned 120,206 shares of the biopharmaceutical company’s stock after selling 31,950 shares during the period. Hodges Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $8,816,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. DLD Asset Management LP purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth about $650,250,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after purchasing an additional 1,425,674 shares during the period. Federated Hermes Inc. increased its holdings in shares of Halozyme Therapeutics by 294.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after purchasing an additional 1,082,638 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth approximately $51,295,000. Finally, Los Angeles Capital Management LLC boosted its holdings in shares of Halozyme Therapeutics by 951.8% during the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock worth $50,650,000 after purchasing an additional 881,094 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $55,733,662.16. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,398 shares of company stock valued at $3,650,592 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.44.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year revenue ($1.397B) and raised visibility into 2026 — management reiterated guidance for materially higher 2026 revenue, sizable adjusted EBITDA and strong non‑GAAP EPS ranges, supporting forward growth expectations. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE
• Positive Sentiment: Royalty momentum and inorganic tech adds — royalty revenue grew strongly (record $868M FY2025) and the company closed acquisitions of Hypercon technologies, which could expand product/enhancement mix and lift future royalty streams. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE
• Positive Sentiment: Street sentiment remains constructive — broker consensus is skewed positive (moderate‑buy) with a median price target near current levels, giving upside support if guidance execution continues. HALO Receives Consensus Rating
• Neutral Sentiment: Top‑line beat but mixed quarter — Q4 revenue of ~$451.8M rose ~51.6% YoY and slightly topped estimates, showing continued ENHANZE/royalty strength even as profitability metrics were weak. Halozyme Surprises With Q4 CY2025 Sales
• Neutral Sentiment: Analyses are watching whether royalty momentum can sustain into 2026 — if royalties and new tech contributions track to guidance, upside is plausible; execution risk remains. Halozyme earnings in focus
• Negative Sentiment: Large EPS miss and reported Q4 loss — Halozyme reported EPS of ($0.24) versus street expectations materially higher (consensus ~+$1.9), producing investor concern about one‑time items, costs or non‑GAAP adjustments behind the gap. Halozyme Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Market reaction and deeper financial details — shares fell after the surprise loss; third‑party summaries show a sizable operating and net loss, rising liabilities and notable insider selling, all of which heighten near‑term risk sentiment. Halozyme Stock Falls on Q4 2025 Earnings

Halozyme Therapeutics Stock Up 1.3%

HALO opened at $80.48 on Wednesday. The firm has a market cap of $9.46 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The business has a 50 day moving average price of $71.55 and a 200 day moving average price of $70.25. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.